These are top 10 stocks traded on the Robinhood UK platform in July
BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ:BLFS), a leading provider of cell processing tools for the cell and gene therapy market, saw its shares jump 7.9% after reporting better-than-expected fourth quarter results and issuing optimistic 2025 guidance.
The company posted a narrower-than-anticipated Q4 loss of -$0.04 per share, beating analyst estimates of -$0.08 per share. Revenue rose 31% YoY to $22.7 million, surpassing the consensus forecast of $22.03 million.
BioLife’s Cell Processing segment, which includes its core biopreservation media products, drove growth with revenue up 37% YoY to $20.3 million. This marked the fifth consecutive quarter of revenue growth for the segment.
"We delivered five consecutive quarters of revenue growth in our cell processing platform, exceeding expectations and outperforming our raised full year guidance," said Roderick de Greef, Chairman and CEO of BioLife Solutions.
Looking ahead, the company expects 2025 revenue of $95.5 million to $99 million, representing 16-20% growth over 2024 and topping the $95.45 million analyst consensus. Cell Processing revenue is forecast to grow 18-21% to $86.5-$89 million.
BioLife also noted its biopreservation media is now embedded in 17 approved cell and gene therapies, with 8 additional approvals or expansions expected in the next 12 months.
The strong results and guidance underscore BioLife’s growing position in the cell and gene therapy market following recent divestitures to focus on its high-margin core business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.